Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe revision tag on the page updated from v3.5.3 to v3.5.4, indicating a minor system update that does not modify study details or results displayed.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page’s platform/site revision label was updated from **v3.5.2** to **v3.5.3**, reflecting a behind-the-scenes release rather than a change to the clinical trial record.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded revision: v3.5.2; removed revision: v3.5.0.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check82 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check103 days agoChange DetectedThe site version badge updated from v3.4.1 to v3.4.2, indicating a backend/frontend revision. No study content or functionality was changed as part of this update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.